CN102257009A - 具有针对dc-sign的结合特异性的配体 - Google Patents
具有针对dc-sign的结合特异性的配体 Download PDFInfo
- Publication number
- CN102257009A CN102257009A CN2009801529594A CN200980152959A CN102257009A CN 102257009 A CN102257009 A CN 102257009A CN 2009801529594 A CN2009801529594 A CN 2009801529594A CN 200980152959 A CN200980152959 A CN 200980152959A CN 102257009 A CN102257009 A CN 102257009A
- Authority
- CN
- China
- Prior art keywords
- lip1
- seq
- sign
- variable domain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10708508P | 2008-10-21 | 2008-10-21 | |
| US61/107085 | 2008-10-21 | ||
| PCT/EP2009/063655 WO2010046337A2 (en) | 2008-10-21 | 2009-10-19 | Ligands that have binding specificity for dc-sign |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102257009A true CN102257009A (zh) | 2011-11-23 |
Family
ID=42062429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801529594A Pending CN102257009A (zh) | 2008-10-21 | 2009-10-19 | 具有针对dc-sign的结合特异性的配体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110257373A1 (enExample) |
| EP (1) | EP2356149A2 (enExample) |
| JP (1) | JP2012506237A (enExample) |
| KR (1) | KR20110071139A (enExample) |
| CN (1) | CN102257009A (enExample) |
| AR (1) | AR073905A1 (enExample) |
| AU (1) | AU2009306424A1 (enExample) |
| BR (1) | BRPI0919714A2 (enExample) |
| CA (1) | CA2740856A1 (enExample) |
| EA (1) | EA201100488A1 (enExample) |
| IL (1) | IL212086A0 (enExample) |
| MX (1) | MX2011004244A (enExample) |
| TW (1) | TW201019962A (enExample) |
| UY (1) | UY32189A (enExample) |
| WO (1) | WO2010046337A2 (enExample) |
| ZA (1) | ZA201102763B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024125271A1 (zh) * | 2022-12-13 | 2024-06-20 | 成都维瑾柏鳌生物医药科技有限公司 | 抗hiv-1的重组蛋白及其应用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110775A1 (es) * | 2008-10-21 | 2011-10-21 | Domantis Ltd | Composicion para dirigirse a las celulas dendriticas |
| WO2013095973A1 (en) * | 2011-12-19 | 2013-06-27 | The Rockefeller University | Hdc-sign binding peptides |
| US20250319024A1 (en) * | 2021-08-27 | 2025-10-16 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to infectious disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004101790A1 (en) * | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| WO2005018610A1 (en) * | 2003-08-21 | 2005-03-03 | Lipotek Pty Ltd | In vivo targeting of dendritic cells |
| CN101182539A (zh) * | 2007-11-06 | 2008-05-21 | 浙江大学 | Dc-sign启动子荧光素酶报告质粒的构建方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0598108A1 (en) * | 1992-06-05 | 1994-05-25 | Dade Produktions AG | Rabbit single domain antibody and use thereof |
| JP2006519763A (ja) * | 2002-11-08 | 2006-08-31 | アブリンクス エン.ヴェー. | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| EP2390270A1 (en) * | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| DE602004017726D1 (de) * | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| AU2005250216B2 (en) * | 2004-06-01 | 2009-12-10 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| CA2588892A1 (en) * | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| EP1841796A2 (en) * | 2004-12-02 | 2007-10-10 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| KR20080003351A (ko) * | 2005-03-18 | 2008-01-07 | 도만티스 리미티드 | 캔디다 항원에 대한 항체 |
| KR20080090414A (ko) * | 2005-12-06 | 2008-10-08 | 도만티스 리미티드 | 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법 |
| JP2009518024A (ja) * | 2005-12-06 | 2009-05-07 | ドマンティス リミテッド | Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法 |
| AU2007209202A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind IL-4 and/or IL-13 |
| CA2663851A1 (en) * | 2006-09-26 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
| US20100143371A1 (en) * | 2006-10-31 | 2010-06-10 | Zhenping Zhu | Intrabodies |
-
2009
- 2009-10-19 WO PCT/EP2009/063655 patent/WO2010046337A2/en not_active Ceased
- 2009-10-19 CA CA2740856A patent/CA2740856A1/en not_active Abandoned
- 2009-10-19 AU AU2009306424A patent/AU2009306424A1/en not_active Abandoned
- 2009-10-19 EP EP09736603A patent/EP2356149A2/en not_active Withdrawn
- 2009-10-19 MX MX2011004244A patent/MX2011004244A/es not_active Application Discontinuation
- 2009-10-19 KR KR1020117011399A patent/KR20110071139A/ko not_active Withdrawn
- 2009-10-19 AR ARP090104011A patent/AR073905A1/es not_active Application Discontinuation
- 2009-10-19 US US13/125,384 patent/US20110257373A1/en not_active Abandoned
- 2009-10-19 CN CN2009801529594A patent/CN102257009A/zh active Pending
- 2009-10-19 TW TW098135298A patent/TW201019962A/zh unknown
- 2009-10-19 EA EA201100488A patent/EA201100488A1/ru unknown
- 2009-10-19 BR BRPI0919714A patent/BRPI0919714A2/pt not_active IP Right Cessation
- 2009-10-19 JP JP2011531514A patent/JP2012506237A/ja active Pending
- 2009-10-20 UY UY0001032189A patent/UY32189A/es unknown
-
2011
- 2011-04-03 IL IL212086A patent/IL212086A0/en unknown
- 2011-04-13 ZA ZA2011/02763A patent/ZA201102763B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004101790A1 (en) * | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| WO2005018610A1 (en) * | 2003-08-21 | 2005-03-03 | Lipotek Pty Ltd | In vivo targeting of dendritic cells |
| CN101182539A (zh) * | 2007-11-06 | 2008-05-21 | 浙江大学 | Dc-sign启动子荧光素酶报告质粒的构建方法 |
Non-Patent Citations (2)
| Title |
|---|
| SI J,ET AL.: "ACCESSION NO:AY73916.1,anti-Toxoplasma gondii SAG1 immunoglobulin S3 light chain variable region partial", 《GENBANK DATABASE》 * |
| 杨帆,杨秀荣: "表面等离子体共振技术在分子生物学中的应用", 《生物工程学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024125271A1 (zh) * | 2022-12-13 | 2024-06-20 | 成都维瑾柏鳌生物医药科技有限公司 | 抗hiv-1的重组蛋白及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010046337A3 (en) | 2010-07-01 |
| ZA201102763B (en) | 2012-09-26 |
| IL212086A0 (en) | 2011-06-30 |
| UY32189A (es) | 2010-05-31 |
| KR20110071139A (ko) | 2011-06-28 |
| AR073905A1 (es) | 2010-12-09 |
| MX2011004244A (es) | 2011-05-25 |
| WO2010046337A2 (en) | 2010-04-29 |
| EP2356149A2 (en) | 2011-08-17 |
| TW201019962A (en) | 2010-06-01 |
| BRPI0919714A2 (pt) | 2015-12-08 |
| US20110257373A1 (en) | 2011-10-20 |
| JP2012506237A (ja) | 2012-03-15 |
| CA2740856A1 (en) | 2010-04-29 |
| EA201100488A1 (ru) | 2011-12-30 |
| AU2009306424A1 (en) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12428497B2 (en) | Multispecific antibody constructs | |
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| CN110831626B (zh) | 单价抗备解素抗体及抗体片段 | |
| WO2019024911A1 (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| JP2010505436A (ja) | コンディショナルな方法で所望の分子に結合するアミノ酸配列 | |
| CN105121467A (zh) | 抗cd47抗体及其使用方法 | |
| EP1888641A1 (en) | Serum albumin binding proteins | |
| KR20070084069A (ko) | Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법 | |
| WO2023174396A1 (zh) | 一种新型免疫调节剂的开发和应用 | |
| EA035517B1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| CN115109156A (zh) | 一种靶向bcma的纳米抗体及其应用 | |
| WO2023142297A1 (zh) | Muc1结合分子及其应用 | |
| CN114685666B (zh) | 抗间皮素纳米抗体及其应用 | |
| CN116284377A (zh) | 抗人血管生成素3纳米抗体及其应用 | |
| CN102257009A (zh) | 具有针对dc-sign的结合特异性的配体 | |
| WO2023051618A1 (zh) | Ctla-4结合分子及其应用 | |
| CN106062193A (zh) | 新型与人tlr2及人tlr4结合的双特异性抗体 | |
| WO2024094076A1 (zh) | 一种gipr结合蛋白及其应用 | |
| WO2022002006A1 (zh) | Fab-HCAb结构的结合蛋白 | |
| TWI906795B (zh) | 特異性結合Claudin 18.2的抗體及其製法和應用 | |
| RU2794359C2 (ru) | Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния | |
| WO2023011650A1 (zh) | 一种多特异性抗体及其用途 | |
| RU2784673C2 (ru) | Конструкции полиспецифических антител | |
| JP2025528101A (ja) | 多重特異性ポリペプチド複合体 | |
| EA050517B1 (ru) | Антигенсвязывающий домен с пониженной скоростью расщепления |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111123 |